Literature DB >> 1745939

Outpatient compliance with theophylline and phenytoin therapy.

R Dowse1, W T Futter.   

Abstract

Poor compliance with prescribed medication is a significant problem in chronic disease states and is often responsible for the apparent failure of therapy. The determinants and extent of non-compliance are commonly incorrectly perceived by doctors. During routine therapeutic drug monitoring of epileptic and asthmatic outpatients at a local day hospital, non-compliance was identified as a significant problem. A compliance study was conducted on 80 epileptic and asthmatic patients to determine the nature and extent of this problem. Non-compliance was measured using four different methods, which were then compared using chi 2 tests. Overall incidence of non-compliance was found to be 63%. Age, sex, standard of education and duration of disease were found to have no association with non-compliance. The most clinically significant finding was that almost half the patients were unaware of the necessity of taking their medication on a continuous basis. No significant differences existed between assessing non-compliance using tablet counts, patient interview and clinic attendance, whereas the method using blood levels gave significantly different results from all the other methods used.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1745939

Source DB:  PubMed          Journal:  S Afr Med J


  3 in total

1.  Measurement of patient compliance.

Authors:  A H Paes; A Bakker; C J Soe-Agnie
Journal:  Pharm World Sci       Date:  1998-04

Review 2.  The patient perspective. What should a new anti-asthma agent provide?

Authors:  L Osman
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Evaluation of self-reported medication adherence and its associated factors among epilepsy patients in Hospital Kuala Lumpur.

Authors:  Nagashekhara Molugulu; Kumar Shiva Gubbiyappa; C R Vasudeva Murthy; Lim Lumae; Anil Tumkur Mruthyunjaya
Journal:  J Basic Clin Pharm       Date:  2016-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.